Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R B Moss

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
The Journal of Infectious Diseases|August 7, 1999
Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogenR B Moss, M R Wallace, W K Giermakowska, et al.
HIV Medicine|December 12, 2001
The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugsJ L Turner, J R Kostman, A Aquino, et al.
Human Gene Therapy|October 9, 2001
A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung diseaseM L Aitken, R B Moss, D A Waltz, et al.
Journal of Human Virology|April 9, 1999
Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjectsR B Moss, L Li, W K Giermakowska, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 1, 1997
Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infectionR B Moss, R J Trauger, W K Giermakowska, et al.
Human Gene Therapy|May 15, 1998
A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosisJ A Wagner, M L Moran, A H Messner, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|August 1, 1996
Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infectionM R Wallace, R B Moss, H J Beecham, et al.
The Journal of Infectious Diseases|August 7, 1999
Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infectionS Sei, S L Sandelli, G Theofan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 18, 2014
Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trialC Conrad, J Lymp, V Thompson, et al.
The Laryngoscope|July 13, 2000
Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinusJ A Wagner, A H Messner, M L Moran, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
The Journal of Infectious Diseases|August 7, 1999
Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogenR B Moss, M R Wallace, W K Giermakowska, et al.
HIV Medicine|December 12, 2001
The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugsJ L Turner, J R Kostman, A Aquino, et al.
Human Gene Therapy|October 9, 2001
A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung diseaseM L Aitken, R B Moss, D A Waltz, et al.
Journal of Human Virology|April 9, 1999
Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjectsR B Moss, L Li, W K Giermakowska, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 1, 1997
Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infectionR B Moss, R J Trauger, W K Giermakowska, et al.
Human Gene Therapy|May 15, 1998
A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosisJ A Wagner, M L Moran, A H Messner, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|August 1, 1996
Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infectionM R Wallace, R B Moss, H J Beecham, et al.
The Journal of Infectious Diseases|August 7, 1999
Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infectionS Sei, S L Sandelli, G Theofan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 18, 2014
Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trialC Conrad, J Lymp, V Thompson, et al.
The Laryngoscope|July 13, 2000
Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinusJ A Wagner, A H Messner, M L Moran, et al.
Pageof 12